Ocular Therapeutix, Inc.
OCUL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $63,723 | $58,443 | $51,494 | $43,522 |
| % Growth | 9% | 13.5% | 18.3% | – |
| Cost of Goods Sold | $5,626 | $5,281 | $4,540 | $4,406 |
| Gross Profit | $58,097 | $53,162 | $46,954 | $39,116 |
| % Margin | 91.2% | 91% | 91.2% | 89.9% |
| R&D Expenses | $127,635 | $61,055 | $53,462 | $50,083 |
| G&A Expenses | $60,653 | $33,940 | $67,980 | $31,880 |
| SG&A Expenses | $102,243 | $74,489 | $72,146 | $67,070 |
| Sales & Mktg Exp. | $41,590 | $40,549 | $4,166 | $35,190 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $229,878 | $135,544 | $125,608 | $117,153 |
| Operating Income | -$171,781 | -$82,382 | -$78,654 | -$78,037 |
| % Margin | -269.6% | -141% | -152.7% | -179.3% |
| Other Income/Exp. Net | -$21,725 | $1,646 | $7,616 | $71,484 |
| Pre-Tax Income | -$193,506 | -$80,736 | -$71,038 | -$6,553 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$193,506 | -$80,736 | -$71,038 | -$6,553 |
| % Margin | -303.7% | -138.1% | -138% | -15.1% |
| EPS | -1.22 | -1.09 | -1.04 | -1.05 |
| % Growth | -11.9% | -4.8% | 1% | – |
| EPS Diluted | -1.22 | -1.02 | -0.97 | -0.98 |
| Weighted Avg Shares Out | 158,265 | 79,827 | 76,875 | 76,393 |
| Weighted Avg Shares Out Dil | 158,265 | 85,597 | 82,644 | 82,162 |
| Supplemental Information | – | – | – | – |
| Interest Income | $20,282 | $3,983 | $798 | $33 |
| Interest Expense | $13,577 | $11,338 | $7,022 | $6,671 |
| Depreciation & Amortization | $3,786 | $2,983 | $2,109 | $2,421 |
| EBITDA | -$176,143 | -$66,415 | -$61,907 | $2,539 |
| % Margin | -276.4% | -113.6% | -120.2% | 5.8% |